Overall survival rates for primary central nervous system lymphoma (PCNSL) have increased significantly over the last four decades thanks to prompt treatment initiation and the use of intensive high-dose methotrexate and rituximab-based protocols, a UK study shows. The observational study was based on patient data from Nottingham University Hospitals Trust, split into two distinct therapeutic ...
Primary CNS lymphoma survival outcomes have improved in the era of MTX and rituximab
By Selina Wellbelove
11 Aug 2021